Cargando…

Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies

Affibodies targeting amyloid-beta (Aβ) could potentially be used as therapeutic and diagnostic agents in Alzheimer’s disease (AD). Affibodies display suitable characteristics for imaging applications such as high stability and a short biological half-life. The aim of this study was to explore brain...

Descripción completa

Detalles Bibliográficos
Autores principales: Faresjö, Rebecca, Lindberg, Hanna, Ståhl, Stefan, Löfblom, John, Syvänen, Stina, Sehlin, Dag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246779/
https://www.ncbi.nlm.nih.gov/pubmed/35538266
http://dx.doi.org/10.1007/s11095-022-03282-2
_version_ 1784739029443411968
author Faresjö, Rebecca
Lindberg, Hanna
Ståhl, Stefan
Löfblom, John
Syvänen, Stina
Sehlin, Dag
author_facet Faresjö, Rebecca
Lindberg, Hanna
Ståhl, Stefan
Löfblom, John
Syvänen, Stina
Sehlin, Dag
author_sort Faresjö, Rebecca
collection PubMed
description Affibodies targeting amyloid-beta (Aβ) could potentially be used as therapeutic and diagnostic agents in Alzheimer’s disease (AD). Affibodies display suitable characteristics for imaging applications such as high stability and a short biological half-life. The aim of this study was to explore brain delivery and retention of Aβ protofibril-targeted affibodies in wild-type (WT) and AD transgenic mice and to evaluate their potential as imaging agents. Two affibodies, Z5 and Z1, were fused with the blood–brain barrier (BBB) shuttle single-chain variable fragment scFv8D3. In vitro binding of (125)I-labeled affibodies with and without scFv8D3 was evaluated by ELISA and autoradiography. Brain uptake and retention of the affibodies at 2 h and 24 h post injection was studied ex vivo in WT and transgenic (tg-Swe and tg-ArcSwe) mice. At 2 h post injection, [(125)I]I-Z5 and [(125)I]I-Z1 displayed brain concentrations of 0.37 ± 0.09% and 0.46 ± 0.08% ID/g brain, respectively. [(125)I]I-scFv8D3-Z5 and [(125)I]I-scFv8D3-Z1 showed increased brain concentrations of 0.53 ± 0.16% and 1.20 ± 0.35%ID/g brain. At 24 h post injection, brain retention of [(125)I]I-Z1 and [(125)I]I-Z5 was low, while [(125)I]I-scFv8D3-Z1 and [(125)I]I-scFv8D3-Z5 showed moderate brain retention, with a tendency towards higher retention of [(125)I]I-scFv8D3-Z5 in AD transgenic mice. Nuclear track emulsion autoradiography showed greater parenchymal distribution of [(125)I]I-scFv8D3-Z5 and [(125)I]I-scFv8D3-Z1 compared with the affibodies without scFv8D3, but could not confirm specific affibody accumulation around Aβ deposits. Affibody-scFv8D3 fusions displayed increased brain and parenchymal delivery compared with the non-fused affibodies. However, fast brain washout and a suboptimal balance between Aβ and mTfR1 affinity resulted in low intrabrain retention around Aβ deposits. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-022-03282-2.
format Online
Article
Text
id pubmed-9246779
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-92467792022-07-02 Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies Faresjö, Rebecca Lindberg, Hanna Ståhl, Stefan Löfblom, John Syvänen, Stina Sehlin, Dag Pharm Res Research Paper Affibodies targeting amyloid-beta (Aβ) could potentially be used as therapeutic and diagnostic agents in Alzheimer’s disease (AD). Affibodies display suitable characteristics for imaging applications such as high stability and a short biological half-life. The aim of this study was to explore brain delivery and retention of Aβ protofibril-targeted affibodies in wild-type (WT) and AD transgenic mice and to evaluate their potential as imaging agents. Two affibodies, Z5 and Z1, were fused with the blood–brain barrier (BBB) shuttle single-chain variable fragment scFv8D3. In vitro binding of (125)I-labeled affibodies with and without scFv8D3 was evaluated by ELISA and autoradiography. Brain uptake and retention of the affibodies at 2 h and 24 h post injection was studied ex vivo in WT and transgenic (tg-Swe and tg-ArcSwe) mice. At 2 h post injection, [(125)I]I-Z5 and [(125)I]I-Z1 displayed brain concentrations of 0.37 ± 0.09% and 0.46 ± 0.08% ID/g brain, respectively. [(125)I]I-scFv8D3-Z5 and [(125)I]I-scFv8D3-Z1 showed increased brain concentrations of 0.53 ± 0.16% and 1.20 ± 0.35%ID/g brain. At 24 h post injection, brain retention of [(125)I]I-Z1 and [(125)I]I-Z5 was low, while [(125)I]I-scFv8D3-Z1 and [(125)I]I-scFv8D3-Z5 showed moderate brain retention, with a tendency towards higher retention of [(125)I]I-scFv8D3-Z5 in AD transgenic mice. Nuclear track emulsion autoradiography showed greater parenchymal distribution of [(125)I]I-scFv8D3-Z5 and [(125)I]I-scFv8D3-Z1 compared with the affibodies without scFv8D3, but could not confirm specific affibody accumulation around Aβ deposits. Affibody-scFv8D3 fusions displayed increased brain and parenchymal delivery compared with the non-fused affibodies. However, fast brain washout and a suboptimal balance between Aβ and mTfR1 affinity resulted in low intrabrain retention around Aβ deposits. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-022-03282-2. Springer US 2022-05-10 2022 /pmc/articles/PMC9246779/ /pubmed/35538266 http://dx.doi.org/10.1007/s11095-022-03282-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Paper
Faresjö, Rebecca
Lindberg, Hanna
Ståhl, Stefan
Löfblom, John
Syvänen, Stina
Sehlin, Dag
Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies
title Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies
title_full Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies
title_fullStr Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies
title_full_unstemmed Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies
title_short Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies
title_sort transferrin receptor binding bbb-shuttle facilitates brain delivery of anti-aβ-affibodies
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246779/
https://www.ncbi.nlm.nih.gov/pubmed/35538266
http://dx.doi.org/10.1007/s11095-022-03282-2
work_keys_str_mv AT faresjorebecca transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies
AT lindberghanna transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies
AT stahlstefan transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies
AT lofblomjohn transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies
AT syvanenstina transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies
AT sehlindag transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies